In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Tolero Pharmaceuticals, Inc.

http://toleropharmaceuticals.com/index.html

Latest From Tolero Pharmaceuticals, Inc.

Asia Deal Watch: Cipla’s Latest Diabetes Partner In India Is Boehringer Ingelheim

Also, deals involving Sumitomo Dainippon, Tolero, Boston Biomedical, Zai Lab, Turning Point, SciClone, EpicentRx, Yuhan, GI Innovation, Takeda, Carmine, HitGen, Morphic, CStone and Burning Rock.

Deals Business Strategies

M&A A Major Pillar Of Sumitomo Dainippon's New Mid-Term Plan

Mid-size Japanese player Sumitomo Dainippon sets aside billions for potential M&A deals under a new business plan designed to fill gaps in its neurology pipeline as it prepares to lose exclusivity for its top global product.

Business Strategies M & A

Gottlieb Wants Timely Approval Of User Fee Bill, Balanced LDT Plan

FDA Commissioner-nominee Scott Gottlieb was approved by the Senate HELP committee April 27, sending his confirmation to the full Senate. Written responses from Gottlieb to senators' questions provided in advance of the vote don't hold any big surprises, but they provide a view into priorities of the incoming official and the lawmakers, including quick user-fee reauthorization, resolving the lab-developed test oversight debate, off-label and "right-to-try" issues and post-market surveillance.

Policy Leadership

Gottlieb Confirmation: Scheduling, Paperwork Delay Committee Vote One Day

FDA Commissioner nominee's answers to questions about his confidential committee paperwork did not arrive until minutes before the committee hearing, but Republicans' scheduling conflicts also may be to blame for the delay.

FDA Leadership
See All

Company Information

UsernamePublicRestriction

Register